stockrowBioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
Follow BCRX
Alert me
BioCryst Pharmaceuticals, Inc. (BCRX) Total debt
BioCryst Pharmaceuticals, Inc.'s total debt at the end of fiscal 2025 was $480.9M, down 42.1% from $830.7M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $839.4M. Over the past ten years it has ranged from $2.4M (fiscal 2015) to $837.7M (fiscal 2023); the current reading is higher than 64% of that period. BioCryst Pharmaceuticals, Inc. ranks 14th of 84 Drug Manufacturers Specialty & Generic companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $480.9M | (42.11%) |
| FY2024 | $830.7M | (0.83%) |
| FY2023 | $837.7M | 13.59% |
| FY2022 | $737.4M | 24.31% |
| FY2021 | $593.2M | 112.25% |
| FY2020 | $279.5M | 420.34% |
| FY2019 | $53.7M | 64.49% |
| FY2018 | $32.7M | 25.77% |
| FY2017 | $26.0M | (51.67%) |
| FY2016 | $53.7M | 2,162.06% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $839.4M | (2.41%) |
| Mar 2026 | $860.1M | 78.86% |
| Dec 2025 | $480.9M | (28.54%) |
| Sep 2025 | $672.9M | (7.62%) |
| 39 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PRGO Perrigo Company plc compare | $3.3B |
| PBH Prestige Consumer Healthcare Inc. compare | $2.0B |
| ALVO Alvotech compare | $1.3B |
| BCRX BioCryst Pharmaceuticals, Inc. | $839.4M |
| TRLV Trulieve Cannabis Corp. compare | $345.0M |
| XERS Xeris Biopharma Holdings, Inc. compare | $189.7M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $94.5M |
| ANIP ANI Pharmaceuticals, Inc. compare | $23.4M |
| RGC Regencell Bioscience Holdings Limited compare | $463.7K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on BCRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement